Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

y Rat Neurons by a GABA-Independent Pathway in presentation P-192. About Neurochem

Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the United States Food and Drug Administration, European Medicines Agency and Swissmedic. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit our Web Site at: www.neurochem.com.

This news release contains forward-looking statements regarding tramiprosate (ALZHEMED(TM)) as well as regarding continuing and further development efforts. These statements are based on the current analysis and expectations of management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials may not provide definitive results regarding safety, tolerability or therapeutic benefits. Even if all the endpoints sought in the clinical trials were met (which is not certain), there is no certainty that regulators would ultimately approve tramiprosate (ALZHEMED(TM)) for sale to the public. Risks and uncertainties may include: failure to demonstrate the safety, tolerability and efficacy of our product, that ac
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:2/27/2015)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: VTAE ).  Such investors are advised ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ... and/or directors have violated Sections 10(b) and 20(a) of ... On February 27, 2015, the Company announced that its ...
(Date:2/27/2015)... N.J. , Feb. 27, 2015  Acsis Inc., ... and serialization solutions, announced today that John DiPalo ... a Supply & Demand Chain Executive 2015 ... executives who are leading initiatives to help prepare their ... of today,s business climate. This year,s list of Provider ...
(Date:2/27/2015)... - La ... monitoraggio dell,infarto congestizio (CHF - Congestive Heart Failure) ...   Vectorious Medical Technologies, società ... il monitoraggio cardiaco destinato a pazienti affetti da ... concluso una raccolta di finanziamenti per 5 milioni ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... NOVATO, Calif., Nov. 21, 2011 Ultragenyx Pharmaceutical, ... for rare and ultra-rare genetic disorders, today announced ... Chief Business Officer. Mr. Kassberg will be responsible ... strategic planning activities, as well as the human ...
... Nov. 21, 2011 Reportlinker.com announces that a ... catalogue: Medical Automation Technologies, Products ... REPORT SCOPE ... Since the enactment of the ...
Cached Medicine Technology:Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team 2Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team 3Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team 4Medical Automation Technologies, Products and Markets 2Medical Automation Technologies, Products and Markets 3Medical Automation Technologies, Products and Markets 4Medical Automation Technologies, Products and Markets 5Medical Automation Technologies, Products and Markets 6Medical Automation Technologies, Products and Markets 7Medical Automation Technologies, Products and Markets 8Medical Automation Technologies, Products and Markets 9Medical Automation Technologies, Products and Markets 10Medical Automation Technologies, Products and Markets 11Medical Automation Technologies, Products and Markets 12Medical Automation Technologies, Products and Markets 13Medical Automation Technologies, Products and Markets 14Medical Automation Technologies, Products and Markets 15
(Date:2/27/2015)... Hills, CA (PRWEB) February 27, 2015 ... Wolf, LLP (BPW) has been chosen as their doc-link ... Dynamics GP, CRM and other complimentary solutions for their ... in working with credit unions. Altec and BPW have ... leveraging doc-link’s integration to Dynamics GP. , “We are ...
(Date:2/27/2015)... Evans, GA (PRWEB) February 27, 2015 In honor ... Center for Primary Care (CPC) South office, is offering tips on ... leading cause of death, but that doesn't mean people have to ... to change some risk factors — such as family history, sex ... to take. , Dr. Scott has six helpful tips to ...
(Date:2/27/2015)... The V Foundation for Cancer Research, one ... excited to announce numerous promotions taking place this March. ... partnerships highlight The V Foundation’s significant work in the ... all to get involved. Awarding 100 percent of ... V Foundation has funded more than $130 million in ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Dr. Andrew ... surgeons , is pleased to announce the expansion of ... open in Delafield. Quintessa has begun seeing patients on ... new Delafield location will offer a variety of state-of-the-art ... Botox, filler injectables, micro laser peels, chemical peels, microdermabrasion, ...
(Date:2/27/2015)... February 27, 2015 Legislation passed ... includes a pharmacy provision to help prevent inappropriate ... pharmacy counter. The Protecting the Integrity of Medicare ... Subcommittee Chairman Kevin Brady (R-TX) and Ranking Member ... the prescription drug abuse epidemic and implement the ...
Breaking Medicine News(10 mins):Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3Health News:Center for Primary Care Celebrates American Heart Month 2Health News:Center for Primary Care Celebrates American Heart Month 3Health News:Center for Primary Care Celebrates American Heart Month 4Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:PCMA Statement on the ‘Protecting the Integrity of Medicare Act’ 2
... , ... ... ... ...
... is not well controlled and on low doses of ... most effective of three possible step-up treatments. National Jewish ... and Lynn Taussig, and colleagues in the NIH-funded Childhood ... 2, 2010, online in the New England Journal ...
... them would lower people,s quality of life, , TUESDAY, March ... caused by kidney failure yield mixed results, depending on the ... People on dialysis with severe anemia, according to the study, ... drugs -- known as erythropoiesis-stimulating agents (ESAs) and marketed as ...
... ... ... ... ...
... ... ... , , ... ...
... eye-opening editorial in the March 2010 issue of the ... Beryl Benacerraf, MD, urges the medical community to use ... imaging test for better diagnosis capability in the evaluation ... the editorial, "Why Has Computed Tomography Won and Ultrasound ...
Cached Medicine News:Health News:Vitamin Shoppe, Inc. To Present at the 2010 Stifel Nicolaus Consumer Conference 2Health News:Vitamin Shoppe, Inc. To Present at the 2010 Stifel Nicolaus Consumer Conference 3Health News:Long-acting beta-agonists most effective step-up therapy for children with poorly controlled asthma 2Health News:For Some on Dialysis, Anemia Drugs Pose Risks 2Health News:For Some on Dialysis, Anemia Drugs Pose Risks 3Health News:For Some on Dialysis, Anemia Drugs Pose Risks 4Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 2Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 4Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 5Health News:AMA Honors Iowa State Representative Mark Smith With Top Government Service Award 2Health News:AMA Honors Iowa State Representative Mark Smith With Top Government Service Award 3Health News:Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly 2
... aluminum cuffs that can be bent to ... joint alignment, unique slot/screw adjustment mechanism allows ... cuff position. Cuffs are configured to offer ... with contractures.,The hinge can be locked in ...
... ACTION Elbow Wrap replaces messy taping and ... and others experiencing epicondylitis. Preferred by doctors ... non-bulky fit. Two overlay straps allow you ... foam lining holds the Elbow Wrap comfortably ...
... is designed to handle post-op elbow arthroscopy, ... Bledsoe Extender Arm Brace should be used ... the elbow is desired. In most cases, ... formed, fitted and adjusted in 5 minutes ...
... contour design of this lightweight brace allows it ... It stabilizes the ankle joint following severe sprains, ... semi-rigid spiral stays move with the ankle and ... help the splint control rotational strains on the ...
Medicine Products: